Clinical Trials Logo

Diabetic Gastroparesis clinical trials

View clinical trials related to Diabetic Gastroparesis.

Filter by:

NCT ID: NCT01696747 Completed - Gastroparesis Clinical Trials

Gastroparesis Registry 2

GpR2
Start date: July 2012
Phase:
Study type: Observational

To expand a registry of patients for the study of the epidemiology, etiology, and degree of morbidity associated with gastroparesis.

NCT ID: NCT01607684 Completed - Diabetes Mellitus Clinical Trials

Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis

Start date: January 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Magnetic Marker Monitoring is an appropriate opportunity to diagnose and to quantify a suspicious gastroparesis in subjects with diabetic polyneuropathy.

NCT ID: NCT01557296 Completed - Clinical trials for Diabetic Gastroparesis

Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis

Start date: September 2007
Phase: Phase 2
Study type: Interventional

The objective of the study is in subjects with Insulin Treated Diabetes Mellitus type 1 or 2 and gastroparesis: - validate radiopaque markers with fluoroscopy with gastric scintigraphy method - study the difference of metabolic control including the frequents of hypoglycaemia, gastrointestinal symptoms, quality of life and nutrition state during dietary treatment of food of small particle size compared with food of large particle size - validate the radiopaque markers method and measurement of the blood glucose and gastrointestinal symptoms after a test meal, against the gastric scintigraphy - determine if the function of gastric emptying can be improved after intervention

NCT ID: NCT01469286 Completed - Clinical trials for Diabetic Gastroparesis

Transcutaneous Electroacupuncture for Gastroparesis

TEA
Start date: March 2010
Phase: Phase 1
Study type: Interventional

Gastroparesis is a common disease defined as delayed emptying of the stomach. It is present in at least 20% of about 150 million patients with diabetes worldwide and in more than 20% of patients with functional dyspepsia that affects about 10%-25% of the general population. Gastroparesis is a refractory disease with a lack of therapeutic options. Common symptoms of gastroparesis include nausea, vomiting, early satiety and abdominal bloating. Electroacupuncture (EA) is a combined procedure with acupuncture and electrical current stimulation instead of manual manipulations of the needles. Recent studies in our lab with EA or transcutaneous EA (TEA) have suggested a therapeutic role of EA or TEA for gastric motility disorders. Improvement has been observed with EA or TEA in gastric emptying as well as dyspeptic symptoms. In this project, a micro-stimulator is designed and developed for the TEA therapy. The micro-stimulator is small enough so that it can be attached to the skin next to the stimulation electrodes and therefore the patient can resume normal daily activity while being treated by TEA. This is not only attractive but also more effective since TEA can be performed more often and for longer durations. This exploratory project is designed to study the feasibility, efficacy and certain mechanisms of the proposed method of "wireless" TEA in patients with gastroparesis. Firstly the feasibility of the chronic use the proposed micro-stimulator will be studied. Secondly, the efficacy of the TEA in improving delayed gastric emptying and symptoms of gastroparesis will be investigated in a double-blinded crossover design in patients with diabetic or idiopathic gastroparesis. Thirdly, possible mechanisms involving pathogeneses of gastroparesis with TEA will be investigated.

NCT ID: NCT01126034 Completed - Clinical trials for Gastroesophageal Reflux Disease

Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention

Start date: March 2007
Phase: N/A
Study type: Interventional

The investigators hypothesized that: 1) an intervention targeted at the prescribing physician would increase the rate of a metoclopramide discontinuation among patients prescribed the medication for questionable or unclear indications; and 2) the discontinuation would be durable.

NCT ID: NCT01030341 Completed - Clinical trials for Diabetic Gastroparesis

Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis

GLUMIT-DG
Start date: May 2011
Phase: N/A
Study type: Interventional

A pilot study to assess the safety, feasibility, and potential (uncontrolled) efficacy of continuous glucose monitoring (CGMS) in conjunction with an insulin pump to improve glycemic control for treatment of type 1 and type 2 diabetic patients with gastroparesis

NCT ID: NCT00845858 Completed - Diabetes Clinical Trials

Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis

Start date: April 2009
Phase: Phase 2
Study type: Interventional

To evaluate the safety and the effectiveness of two doses of metoclopramide nasal spray solution, 10 mg and 14 mg, compared to placebo in reducing the symptoms of diabetic gastroparesis.

NCT ID: NCT00139893 Completed - Clinical trials for Diabetic Gastroparesis

A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis

Start date: June 2005
Phase: N/A
Study type: Interventional

To determine whether a new Orally Disintegrating Tablet of Reglan (metoclopramide) is metabolized faster than the conventional Reglan tablet in patients with diabetic gastroparesis, pharmacokinetics following a single 10 mg dose of each formulation are being compared. Subjects must be 18 or older, have Type 1 or 2 diabetes with documented gastroparesis and agree to withhold medications for gastroparesis for 3 days prior to each dosing. Exclusion criteria include serum glucose >300 mg/dL, Hb1Ac >10%, and concurrent illness interfering with gastrointestinal motility. Subjects will stay in the clinic overnight, and pharmacokinetic sampling will continue for 8 hours after the first morning dose. The time (Tmax) and amount (Cmax) of peak concentration and the area under the curve (AUC) from time zero to 8 hr will be compared for the 2 formulations.